Supreme Court ruling could reshape access to medication abortions
The case may limit telemedicine abortions and block at home pill regimens, threatening access in states with bans. Aid Access mails about 6,000 doses monthly. advocates vow to persevere or switch to misoprostol only. Analysts warn a ruling could erode FDA authority and stifle medical innovation nationwide.
MENTIONED IN THIS ARTICLE
Supreme Court
Aid Access
Rebecca Gomperts
Supreme Court review on safety and access to mifepristone pill
The case questions FDA safety handling and mail order access for mifepristone, with medical groups saying it is among the safest FDA approved drugs while opponents cite alleged emergency complications. The article surveys safety rates, ER visits, and the stakes for abortion access in the upcoming ruling.
MENTIONED IN THIS ARTICLE
U.S. Supreme Court
Food and Drug Administration
FDA
Supreme Court
American College of Obstetricians and Gynecologists
Ashma Upadhyay
Brett M. Kavanaugh
Congress
Trump
John G. Roberts Jr
Roberts
Biden Administration
Washington Post-Abc News
Republican Study Committee
Congressional
House
America
Christina Francis
American Association of Pro- Life Obstetricians
Also Mentioned on This Page
Main Hospital
Wafaa Sharafa and
Samy Magdy
The
Associated Press
Rafah
Gaza Strip
Gaza
United Nations
Israel
Shifa
Hamas
Kareem Ayman Hathat
Shifa Hospital
U.N. Agency For Palestinian Refugees
UNRWA
Philippe Lazzarini
U.N
Anténio Guterres
Guterres
Egypt
World Health Organization
Tedros Adhanom Ghebreyesus
Jameel al-Ayoubi
Abed Radwan
al-Amal
Nasser
Khan Younis
Palestinian Red Crescent Society
Health Ministry
5Th Circuit
Fdas
High Court
Trumpera Department of Health and Human Services
Laura Ungar
Matthew Perrone
Mifepristone
Upadhyay
University of California
San Francisco
U.S
Pratima Gupta
Gupta
James R. Lawrence III
Donald Trump
Holly Fernandez Lynch
Perelman School of Medicine
University of Pennsylvania
Samuel A. Alito Jr
Biden
White House
Kansas
Kentucky
Ohio
RFE